



Universiteit  
Leiden  
The Netherlands

**From data to models : reducing uncertainty in benefit risk assessment :  
application to chronic iron overload in children**

Bellanti, F.

**Citation**

Bellanti, F. (2015, September 24). *From data to models : reducing uncertainty in benefit risk assessment : application to chronic iron overload in children*. Retrieved from <https://hdl.handle.net/1887/35437>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/35437>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/35437> holds various files of this Leiden University dissertation

**Author:** Bellanti, Francesco

**Title:** From data to models : reducing uncertainty in benefit-risk assessment : application to chronic iron overload in children

**Issue Date:** 2015-09-24

**FROM DATA TO MODELS: REDUCING UNCERTAINTY IN BENEFIT-RISK ASSESSMENT**  
APPLICATION TO CHRONIC IRON OVERLOAD IN CHILDREN

Francesco Bellanti

Ph.D. Thesis, Leiden University, September 2015



# **FROM DATA TO MODELS: REDUCING UNCERTAINTY IN BENEFIT-RISK ASSESSMENT**

Application to chronic iron overload in children

## **Proefschrift**

ter verkrijging van

de graad van Doctor aan de Universiteit Leiden,  
op gezag van Rector Magnificus prof.mr. C.J.J.M. Stolker,  
volgens besluit van het College van Promoties  
te verdedigen op donderdag 24 september 2015  
klokke 11:15 uur

door

**Francesco Bellanti**

geboren te Messina, Italië  
in 1986

Promotor Prof. Dr. M. Danhof

Co-promotor Prof. Dr. O.E. Della Pasqua

Promotiecommissie Prof. Dr. P.H. van der Graaf

Prof. Dr. C.A.J. Knibbe

Prof. Dr. G. Pons, Université Paris Descartes, Parijs

Prof. Dr. J. van den Anker, Universitäts Kinderspital, Basel

Prof. Dr. J.J. Meulman, Leiden University

*“If you want to go fast, go alone*

*If you want to go far, go together”*

African proverb

a Simona

The research leading to this thesis is part of the DEferiprone Evaluation in Paediatrics (DEEP) project, supported by the FP7 Framework Research Program “HEALTH-2010.4.2-1: Off-patent medicines for children”. The research has been performed at the Division of Pharmacology of the Leiden Academic Centre for Drug Research (LACDR), Leiden University, Leiden, the Netherlands.

The printing of this thesis was financially supported by:

Quantitative Solutions B.V.

GlaxoSmithKline

Thalassaemia International Federation

Cover and layout by Daniele Bertucelli

Printed by GVO printers & designers B.V., Ede, the Netherlands

ISBN: 978-90-6464-901-1

©2015 Francesco Bellanti (francesco\_bellanti@libero.it)

No part of this thesis may be reproduced or transmitted in any form or by any means without written permission of the author.



# TABLE OF CONTENTS

<b>Section I</b>	<b>General introduction</b>	<b>9</b>
Chapter 1	Integration of PKPD relationships into Benefit-Risk Analysis	11
Chapter 2	Model-informed benefit-risk assessment of iron chelation in transfusion-dependent haemoglobinopathies - Scope and intent of the investigation	49
<b>Section II</b>	<b>Optimising evidence generation in paediatric trials</b>	<b>65</b>
Chapter 3	Population pharmacokinetics of deferiprone in healthy subjects	67
Chapter 4	Sampling optimisation in pharmacokinetic bridging studies: use of deferiprone in children with $\beta$ -thalassaemia	87
Chapter 5	Model-based dosing recommendations for the use of deferiprone in children affected by transfusional iron overload younger 6 years of age	109
<b>Section III</b>	<b>Integrated evaluation of efficacy and safety by modelling and simulation</b>	<b>129</b>
Chapter 6	A disease model for iron overload in patients affected by transfusion-dependent diseases	131
Chapter 7	Model-based optimisation of deferoxamine chelation therapy	153
Chapter 8	Model-based characterisation of the acute and long-term unfavourable effects of iron chelation therapy	177
<b>Section IV</b>	<b>Clinical Trial Simulations: accounting for exposure, disease progression and uncertainty in benefit-risk analysis</b>	<b>201</b>
Chapter 9	Model-based evaluation of benefit-risk balance in children	203
<b>Section V</b>	<b>Conclusion and perspectives</b>	<b>227</b>
Chapter 10	Model-informed assessment of the benefit-risk profile of medicines for children: summary, conclusions and perspectives	229
Chapter 11	Nederlandse samenvatting (Synopsis in Dutch)	247

